NCT06760364招募中1 期
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2024年12月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Safety and Tolerability
研究概览
简要总结
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
详细描述
3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) review the avaliable safety, PK and preliminary efficacy data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and sign a written informed consent documen；
- •At the date of signing ICF, 18 ~70 years old, male or female；
- •Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
- •Positive mesothelin expression;
- •At least one measurable lesion at baseline per RECIST version 1.1；
- •The expected survival time is more than 12 weeks;
- •ECOG 0-1 points;
- •Adequate organ functions.
排除标准
- 未提供
研究组 & 干预措施
CHT102 infusion
Experimental
CHT102 will be dosing by arterial infusion.
干预措施: CHT102 (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: 2 years
Treatment-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
次要结局
- pharmacokinetics (PK)(6 months)
- PD(6 months)
- Progress-free survival(PFS)(2 years)
- Disease control rate (DCR)(At 4 weeks, and overall)
- Objective response rate (ORR)(At 4 weeks, and overall)
- Overall survival (OS )(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerOvarian CancerNCT05372692Weijia Fang, MD3
尚未招募
1 期
MSLN-targeted CAR-T Cells in Solid Tumors.Mesothelin-positive Advanced Malignant Solid TumorsNCT05783089Cancer Institute and Hospital, Chinese Academy of Medical Sciences87
终止
1 期
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaMesotheliomaNCT03436732National Cancer Institute (NCI)5
已完成
1 期
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsNeoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, ExtrahepaticAdenocarcinoma, PancreaticNCT04034238National Cancer Institute (NCI)19
终止
1 期
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8NCT04809766Fred Hutchinson Cancer Center9